ViruSure is acquired by Asahi Kasei Medical

Virusure Forschung und Entwicklung GmbH (ViruSure), a leading contract research organization providing pathogen safety testing services for the global biopharmaceutical industry announced today that it has been acquired by Asahi Kasei Medical Co., Ltd. (Asahi Kasei Medical).

The acquisition is part of a strategic expansion and reinforcement of Asahi Kasei Medical’s bioprocess business, centered on Planova™ virus removal filters used in the manufacturing process for biotherapeutics such as plasma derivatives and biopharmaceuticals.  It is indicative of Asahi Kasei Medical’s continuing strategic efforts to develop businesses that contribute to the safety of and efficient manufacture of biotherapeutics.

Because biologically derived substances are used in the process of manufacturing biotherapeutics, biosafety tests are required at each step of research, development, and manufacture to prevent harm from viruses or other infectious agents.  Driven by strong growth in the biotherapeutics industry, demand for ViruSure’s biosafety testing services and cell banking services thus continues to increase year by year.  Such services not only heighten safety but also facilitate the development of pharmaceutical products and contribute to the widespread adoption of high-quality therapies. 

By enhancing Asahi Kasei Medical’s ability to provide wide-ranging support to manufacturers of biotherapeutics, including broader services related to bioprocess development and manufacturing, this acquisition creates new opportunities for further growth of both Asahi Kasei Medical and ViruSure.

”We are very happy to now be in strategic partnership with Asahi Kasei Medical, a company that shares our strategic goal of providing customers in the biopharmaceutical market with the best possible level of service and scientific expertise. We believe that this partnership will strengthen ViruSure’s presence in the biosafety testing arena as well as providing a strong base from which to further grow and expand the range of services that we can offer” stated Andy Bailey, CEO and co-founder of ViruSure.

Further information on Asahi Kasei Medical’s bioprocess business can be found at

About ViruSure GmbH

ViruSure is an established CRO offering a wide range of services in the areas of virus and prion safety testing for biopharmaceutical products, cell banking and cell bank characterization services and in vivo biosafety studies (adventitious agent testing, tumorigenicity testing, oncogenicity testing) and molecular and potency testing, all required by pharma and biotech companies specializing on biological products (e.g. recombinant proteins, vaccines, human and animal derived biological products, cell based therapies). The company brings a wealth and breadth of expertise to ensure that biopharmaceutical companies meet all relevant pathogen safety testing requirements. Our goal is simple - to offer the highest level of quality, customer service and regulatory compliance for pathogen safety testing. Our state of the art facilities located in Vienna, Austria are validated and certified to both GMP and GLP standards and all testing services are supported by a state of the art risk based quality management system which ensures we remain cutting edge partner dedicated to providing, first and foremost, a quality service to the biopharmaceutical industry.

Andy Bailey
ViruSure GmbH, CEO / Operations Director       

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)